| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/24/2013 | WO2013012446A1 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| 01/24/2013 | WO2013012414A1 Dosing regimens for treatment of cea-expressing cancers |
| 01/24/2013 | WO2013012022A1 Stable protein-containing preparation containing argininamide or analogous compound thereof |
| 01/24/2013 | WO2013011942A1 Mutant canine madness virus and vaccine |
| 01/24/2013 | WO2013011509A1 BACILLUS ANTHRACIS HtrA-DEFECTIVE-DERIVED VACCINES |
| 01/24/2013 | WO2013011431A1 A topical composition for the treatment of alopecia |
| 01/24/2013 | WO2013011247A1 Attenuated plasmodium with deactivated hmgb2 gene, as vaccine |
| 01/24/2013 | WO2013011135A1 Ceramide c16-cer and cers6 in the treatment and diagnosis of multiple sclerosis (ms) |
| 01/24/2013 | WO2013011095A1 Dosage of dnak |
| 01/24/2013 | WO2013011063A1 Antagonistic antibodies against oscar |
| 01/24/2013 | WO2013011062A2 Oscar antagonists |
| 01/24/2013 | WO2013011061A1 Antagonistic antibodies against oscar |
| 01/24/2013 | WO2013011059A1 Antagonist antibodies against oscar |
| 01/24/2013 | WO2013011021A1 Use of c-fms antagonists |
| 01/24/2013 | WO2013010749A1 Sequential anti - ctla4 and targeted il-2 therapy |
| 01/24/2013 | WO2013010300A1 Sequential and repeated application of four or more hiv vector gene vaccines |
| 01/24/2013 | WO2013010274A1 Methods for diagnosing and treating alzheimer's disease by administering an ανίίangiogenic agent |
| 01/24/2013 | WO2013010260A1 Isolated brachyspira and methods and compositions for expanding and isolating brachyspira |
| 01/24/2013 | WO2012157989A3 Avirulent modified salmonella gallinarum strains and pharmaceutical composition using the same |
| 01/24/2013 | WO2012149393A9 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
| 01/24/2013 | WO2012140424A3 Vaccine compositions comprising an antigen conjugated or fused to a toxin and a further antigen |
| 01/24/2013 | WO2012099805A3 Nanoparticle based immunological stimulation |
| 01/24/2013 | WO2012083302A3 Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| 01/24/2013 | WO2012021287A9 Methods for the treatment and prevention of metabolic disorders |
| 01/24/2013 | US20130024956 Antibodies to cd40 |
| 01/24/2013 | US20130023736 Systems for drug delivery and monitoring |
| 01/24/2013 | US20130023714 Medical and Imaging Nanoclusters |
| 01/24/2013 | US20130023485 Parenteral formulations of peptides for the treatment of systematic lupus erythematosus |
| 01/24/2013 | US20130023030 Recovery of recombinant human parainfluenza virus type 2 (hypiv2) from cdna and use of recombinant hpiv2 in immunogenic compositions and as vectors to elicit immune responses against piv and other human pathogens |
| 01/24/2013 | US20130022671 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/24/2013 | US20130022664 E.coli lpfa antigen for prevention and treatment of infectious diseases |
| 01/24/2013 | US20130022661 Bio-remodable bone augmentation device and method |
| 01/24/2013 | US20130022640 Immune modulators relating to foxo3a |
| 01/24/2013 | US20130022639 Expression of meningococcal fhbp polypeptides |
| 01/24/2013 | US20130022638 Tuberculosis Vaccine |
| 01/24/2013 | US20130022637 Recombinant baculovirus vaccine |
| 01/24/2013 | US20130022634 New composition and methods for treatment of autoimmune and allergic diseases |
| 01/24/2013 | US20130022633 MENINGOCOCCAL fHBP POLYPEPTIDES |
| 01/24/2013 | US20130022632 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| 01/24/2013 | US20130022631 Vaccine for chikungunya virus infection |
| 01/24/2013 | US20130022630 Method for treating amyloid disease |
| 01/24/2013 | US20130022629 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| 01/24/2013 | US20130022628 Acyl pseudopeptides which carry a functionalized auxiliary arm |
| 01/24/2013 | US20130022627 Combination Therapy With Antibody-Drug Conjugates |
| 01/24/2013 | US20130022626 Long-acting human follicle-stimulating hormone formulation using immunoglobulin fragment |
| 01/24/2013 | US20130022625 Stabilized Antibody-Containing Liquid Formulations |
| 01/24/2013 | US20130022624 Anti-epidermal growth factor receptor antibodies and uses thereof |
| 01/24/2013 | US20130022623 Antibodies that specifically bind to tim3 |
| 01/24/2013 | US20130022622 Compounds for the treatment of autism |
| 01/24/2013 | US20130022621 Antibody formulation and therapeutic regimens |
| 01/24/2013 | US20130022620 Assays and methods pertaining to pre-amyloid intermediates |
| 01/24/2013 | US20130022619 Methods and compositions for inhibiting hiv transmission |
| 01/24/2013 | US20130022618 Human cytomegalovirus neutralizing antibodies and use thereof |
| 01/24/2013 | US20130022617 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 01/24/2013 | US20130022616 Interleukin-31 Monoclonal Antibody |
| 01/24/2013 | US20130022615 Compositions and Methods for Antibodies Targeting Complement Protein C5 |
| 01/24/2013 | US20130022614 IgE ANTIBODIES FOR THE TREATMENT OF CANCER |
| 01/24/2013 | US20130022613 Wise/sost nucleic acid sequences and amino acid sequences |
| 01/24/2013 | US20130022612 Methods and compositions for malaria prophylaxis |
| 01/24/2013 | US20130022611 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| 01/24/2013 | US20130022610 Methods of decreasing glycosylated hemoglobin in patients with dyslipidemia |
| 01/24/2013 | US20130022609 Method of treating androgen independent prostate cancer |
| 01/24/2013 | US20130022608 FULL-LENGTH IgG IMMUNOGLOBULINS CAPABLE OF RECOGNIZING A HETEROSUBTYPE NEUTRALIZING EPITOPE ON THE HEMAGGLUTININ STEM REGION AND USES THEREOF |
| 01/24/2013 | US20130022607 Mucosal vascular addressins and uses thereof |
| 01/24/2013 | US20130022606 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 01/24/2013 | US20130022605 Antagonists against tnfr1 and methods of use therefor |
| 01/24/2013 | US20130022604 Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa |
| 01/24/2013 | US20130022603 Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa |
| 01/24/2013 | US20130022602 Methods and compositions to modulate antiviral and immune activity responses |
| 01/24/2013 | US20130022601 Trivalent, bispecific antibodies |
| 01/24/2013 | US20130022600 Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| 01/24/2013 | US20130022599 Method of treating fibroproliferative disorders |
| 01/24/2013 | US20130022598 Dual Specific Immunotoxin for Brain Tumor Therapy |
| 01/24/2013 | US20130022597 Antibodies Directed To GPNMB And Uses Thereof |
| 01/24/2013 | US20130022596 Methods and compositions for diagnostic use in cancer patients |
| 01/24/2013 | US20130022595 Variants of humanized immunomodulatory monoclonal antibodies |
| 01/24/2013 | US20130022594 Selective fak inhibitors |
| 01/24/2013 | US20130022593 Methods of diagnosing endometriosis |
| 01/24/2013 | US20130022571 Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| 01/24/2013 | US20130022551 DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
| 01/24/2013 | US20130022547 Attenuated mycoplasma gallisepticum strains |
| 01/24/2013 | US20130022544 Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| 01/24/2013 | US20130022543 Method for Treating and Confirming Diagnosis of Exertional Compartment Syndrome |
| 01/24/2013 | US20130022541 FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death |
| 01/24/2013 | US20130022540 Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| 01/24/2013 | US20130022539 Ovr115 antibody compositions and methods of use |
| 01/24/2013 | US20130019860 Methods and compositions for the preparation of aerosols |
| 01/24/2013 | CA2842345A1 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| 01/24/2013 | CA2842195A1 Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
| 01/24/2013 | CA2842169A1 Anti-cxcr4 antibodies and methods of use |
| 01/24/2013 | CA2842068A1 Isolated brachyspira and methods and compositions for expanding and isolating brachyspira |
| 01/24/2013 | CA2842055A1 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| 01/24/2013 | CA2842034A1 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells |
| 01/24/2013 | CA2841745A1 Rspo binding agents and uses thereof |
| 01/24/2013 | CA2841164A1 Attenuated plasmodium with deactivated hmgb2 gene, as vaccine |
| 01/24/2013 | CA2841015A1 Dosage of dnak |
| 01/24/2013 | CA2841013A1 Use of c-fms antagonists |
| 01/23/2013 | EP2548960A1 Nucleic acids comprising formula (NuGIXmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvant |
| 01/23/2013 | EP2548895A1 Modified saccharides |
| 01/23/2013 | EP2548890A1 Anti MIF antibodies |